Kraig Biocraft Laboratories Enters Next Phase Of Business Plan, Signs Deal With Contract Manufacturer To Produce Metric Tons Of Recombinant Spider Silk

ANN ARBOR, Mich. — July 18, 2022 — Kraig Biocraft Laboratories Inc., the biotechnology company focused on the development and commercialization of spider silk, announces the signing of its first third-party production contract for large scale manufacturing of the company’s recombinant spider silk. The company expects to immediately begin operations with this contractor to produce hundreds of kilograms of spider silk per month and to achieve production levels reaching multiple metric tons of spider silk per month as early as the first quarter of 2023. The contractor is in possession of the company’s specialized eggs and anticipates a 90-day ramp-up for the first deliveries under the contract.

Pilot testing with this contractor during the first two quarters of 2022 demonstrated the capacity and expertise of this manufacturer to operate at a large scale and with excellent quality.

Under the contract terms, Kraig Labs will become a minority owner of the silk producer. Kraig Labs will have complete access to the manufacturer’s financial records and an onsite presence to ensure the proper handling and security of the company’s propriety spider silk technology.

“Our business model was designed to leverage the existing silk production infrastructure. The signing of this agreement rapidly expands our access into that production network and brings us to the next critical stage in our business plan,” said company COO Jon Rice. “Working with this contract manufacturer, we will soon be ready to deliver metric tons of eco-responsible and cost-effective spider silk to the consumer markets.”

In the coming days, the company plans to release the first in a series of behind-the-scenes videos looking into its operations in Vietnam and the commercialization of its spider silk materials.

Posted: July 18, 2022

Source: Kraig Biocraft Laboratories, Inc.